These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 18198653)

  • 1. [The proper use of quinolones to the elderly patient with community-acquired pneumonia examined by Monte Carlo simulation].
    Yanagihara K; Morinaga Y; Fukushima K; Nakamura S; Kurihara S; Seki M; Izumikawa K; Kakeya H; Yamamoto Y; Miyazaki Y; Hirakata Y; Tashiro T; Kohno S
    Jpn J Antibiot; 2007 Oct; 60(5):251-6. PubMed ID: 18198653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
    Noreddin AM; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical investigation on administration method of gatifloxacin based on PK/PD theory].
    Mikamo H; Tanaka K; Watanabe K; Tamaya T; Izumi K
    Jpn J Antibiot; 2006 Oct; 59(5):364-72. PubMed ID: 17180805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effect of gatifloxacin, 200 mg daily, on bacterial community-acquired pneumonia in the elderly.
    Okimoto N; Kibayashi T; Mimura K; Yamato K; Kurihara T; Honda Y; Osaki K; Asaoka N; Ohba H
    J Infect Chemother; 2005 Dec; 11(6):274-7. PubMed ID: 16369733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prediction on the efficacy of fluoroquinolones for anaerobic infections using Monte Carlo simulation].
    Mikamo H; Tanaka K; Watanabe K
    Jpn J Antibiot; 2007 Dec; 60(6):335-43. PubMed ID: 18447205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones.
    Yamagishi Y; Shibata T; Nakagawa S; Nomura N; Mitsuyama J; Mikamo H
    Jpn J Infect Dis; 2017 Nov; 70(6):616-620. PubMed ID: 28890509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model.
    Ambrose PG; Forrest A; Craig WA; Rubino CM; Bhavnani SM; Drusano GL; Heine HS
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4351-5. PubMed ID: 17875992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].
    Nakamura T; Shimizu C; Hirakawa K; Inui S; Okuda K; Nakata C; Fujimoto H; Okura H; Uemura Y; Takahashi H
    Jpn J Antibiot; 2009 Jun; 62(3):194-202. PubMed ID: 19882980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of clinical dosage of gatifloxacin for respiratory tract infections in elderly patients based on pharmacokinetics/pharmacodynamics (PK/PD).
    Niki Y; Yoshida K; Miyashita N; Oka M; Hara H; Kishimoto M; Okimoto N; Kawanishi M; Uno M; Kamao T; Yoneyama H; Nakamura J; Kimura M; Watanabe M; Tanimukai T; Moriya O; Matsushima T
    J Infect Chemother; 2008 Aug; 14(4):296-304. PubMed ID: 18709533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae.
    Yanagihara K; Fukuda Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
    Chemotherapy; 2004 Jun; 50(3):107-12. PubMed ID: 15282438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
    Noreddin AM; Reese AA; Ostroski M; Hoban DJ; Zhanel GG
    Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction.
    Ambrose PG; Bhavnani SM; Cirincione BB; Piedmonte M; Grasela TH
    J Antimicrob Chemother; 2003 Sep; 52(3):435-40. PubMed ID: 12917247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis.
    Yoshida K; Okimoto N; Kishimoto M; Fukano H; Hara H; Yoneyama H; Moriya O; Kawanishi M; Kimura M; Matsushima T; Niki Y
    J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia.
    Press RA
    Pharmacotherapy; 2001 Jul; 21(7 Pt 2):100S-104S. PubMed ID: 11446520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
    Yu W; Ji J; Xiao T; Ying C; Fang J; Shen P; Xiao Y
    Drug Des Devel Ther; 2017; 11():1951-1956. PubMed ID: 28721014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gatifloxacin in community-acquired respiratory tract infection.
    Sethi S
    Expert Opin Pharmacother; 2003 Oct; 4(10):1847-55. PubMed ID: 14521494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.
    Öbrink-Hansen K; Hardlei TF; Brock B; Jensen-Fangel S; Kragh Thomsen M; Petersen E; Kreilgaard M
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2398-404. PubMed ID: 25666151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.